Security Snapshot

4D Molecular Therapeutics, Inc. - COMMON STOCK (FDMT) Institutional Ownership

CUSIP: 35104E100

13F Institutional Holders and Ownership History from Q4 2020 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

79

Shares (Excl. Options)

11.96MFull value: 11,960,362 · shares · 30 Sep 2026

Price

$14.31

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / COMMON STOCK
Symbol
FDMT on Nasdaq
All holders as of 30 Sep 2026
Q3 2026
Total 13F shares
11,960,362
Latest holder snapshot 5 signals
Total 13F value
$171,124,276
Portfolio coverage rank
0%
Share change
+232,375
Value change
+$3,419,417
Number of holders
79
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
54,876,111
SEC-reported price per share
$12.56
Insider filing price
$12.56
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • FDMT - 4D Molecular Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 35104E100.
  • 79 institutions reported positions in Q3 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 156 to 79 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $771.24MFull value: $771,240,409 · USD · 30 Jun 2026
    to
    $171.12MFull value: $171,124,276 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 79 institutions filings for Q3 2026.

Open SEC evidence

Security key

35104E100

13F reference period

Q3 2026

13F holders

79

13D/G owners

9

CIK / CUSIP context first

Open Q3 2026 holders FDMT full holder history 4D Molecular Therapeutics, Inc. SEC filings 4D Molecular Therapeutics, Inc. company facts 4D Molecular Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
FDMT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 10% 0% $52,609,747 -$4,927,498 5,346,519 -8.6% BVF PARTNERS L P/IL 31 Mar 2026
JANUS HENDERSON GROUP PLC 10% +28% $48,852,550 +$5,691,163 5,247,151 +13% JANUS HENDERSON GROUP PLC 31 Mar 2026
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $50,239,320 -$5,984,983 5,105,622 -11% RA Capital Management, L.P. 31 Mar 2026
GOLDMAN SACHS GROUP INC 7.5% -21% $33,688,569 -$1,079,634 4,286,077 -3.1% THE GOLDMAN SACHS GROUP, INC. 31 Dec 2025
Novo Holdings A/S 6.4% -5.7% $28,694,793 +$3,739,293 3,650,737 +15% Novo Holdings A/S 31 Dec 2025
BlackRock, Inc. 6.6% -15% $26,613,959 -$4,803,137 3,062,596 -15% BlackRock, Inc. 30 Sep 2025
STATE STREET CORP 4.5% -16% $31,015,978 -$2,994,932 2,469,425 -8.8% STATE STREET CORPORATION 30 Sep 2026
Venrock Healthcare Capital Partners III, L.P. 1.5% -82% $2,202,200 -$7,393,006 677,600 -77% Venrock Healthcare Capital Partners III, L.P. 31 Mar 2025
Deep Track Capital, LP 1.3% $1,982,175 609,900 Deep Track Capital, LP 31 Dec 2024
As of 30 Sep 2026, 79 institutional investors reported holding
11.96MFull value: 11,960,362 · shares · 30 Sep 2026
shares of 4D Molecular Therapeutics, Inc. - COMMON STOCK (FDMT). This represents 22% of the company’s total
54.88MFull value: 54,876,111 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
21%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
STATE STREET CORP 4.5% 2,469,425 -15% 0% $35,337,472
VANGUARD CAPITAL MANAGEMENT LLC 3.9% 2,140,758 +2% 0% $30,634,247
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,184,271 +4.9% 0% $16,950,907
MORGAN STANLEY 2% 1,090,649 +117% 0% $15,607,188
DIMENSIONAL FUND ADVISORS LP 1.4% 787,000 +7.7% 0% $11,263,085
VANGUARD PORTFOLIO MANAGEMENT LLC 1.1% 578,930 -0.17% 0% $8,284,488
DEUTSCHE BANK AG\ 1% 546,088 -23% 0% $7,814,519
RENAISSANCE TECHNOLOGIES LLC 0.75% 411,786 -33% 0.01% $5,892,658
VANGUARD FIDUCIARY TRUST CO 0.55% 300,719 +8.9% 0% $4,303,289
Invesco Ltd. 0.47% 260,116 +73% 0% $3,722,260
RAYMOND JAMES FINANCIAL INC 0.44% 241,860 -0.2% 0% $3,461,017
Propel Bio Management, LLC 0.33% 179,154 -29% 1.4% $2,563,694
FEDERATED HERMES, INC. 0.32% 176,677 -21% 0% $2,528,248
Perigon Wealth Management, LLC 0.27% 146,185 0% 0.03% $2,091,907
AMERICAN CENTURY COMPANIES INC 0.23% 127,965 +12% 0% $1,831,179
HUSSMAN STRATEGIC ADVISORS, INC. 0.19% 105,000 0.32% $1,502,550
Privium Fund Management B.V. 0.16% 90,110 0% 0.25% $1,289,474
Assenagon Asset Management S.A. 0.15% 83,333 0% 0% $1,192,495
ALPS ADVISORS INC 0.13% 73,175 +38% 0% $1,047,134
TD ASSET MANAGEMENT INC 0.11% 60,758 +18% 0% $880,383
Quantinno Capital Management LP 0.11% 60,506 +4.2% 0% $865,841
Fisher Asset Management, LLC 0.11% 58,546 -11% 0% $837,793
BNP PARIBAS FINANCIAL MARKETS 0.1% 53,624 0% $767,359
Rafferty Asset Management, LLC 0.09% 50,998 +14% 0% $729,781
Affinity Asset Advisors, LLC 0.09% 50,000 0.04% $715,500

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
24
Headline period
Q3 2026
Rows shown
1-24 of 24
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 11,960,362 $171,124,276 +$3,419,417 $14.31 79
2026 Q2 58,026,961 $771,240,409 +$94,608,520 $13.30 156
2026 Q1 50,674,005 $471,361,517 -$20,210,521 $9.31 152
2025 Q4 53,383,506 $400,365,574 +$104,755,232 $7.50 151
2025 Q3 39,480,388 $343,063,699 -$4,201,365 $8.69 129
2025 Q2 40,369,426 $149,859,289 -$9,235,482 $3.71 117
2025 Q1 43,058,381 $139,823,044 -$22,403,324 $3.23 122
2024 Q4 46,814,824 $260,642,119 -$79,332,651 $5.57 140
2024 Q3 57,948,767 $626,374,639 -$34,446,524 $10.81 135
2024 Q2 57,307,189 $1,203,018,791 +$3,520,347 $20.99 138
2024 Q1 56,228,706 $1,790,823,856 +$449,592,828 $31.86 146
2023 Q4 42,433,937 $859,819,319 +$24,792,782 $20.26 111
2023 Q3 41,913,779 $533,559,212 +$5,221,810 $12.73 110
2023 Q2 41,248,927 $745,334,512 +$197,052,931 $18.07 100
2023 Q1 30,404,028 $522,337,328 +$34,968,755 $17.19 94
2022 Q4 28,011,571 $622,110,124 +$47,681,640 $22.21 97
2022 Q3 26,181,987 $210,496,945 +$1,974,268 $8.04 84
2022 Q2 26,027,061 $181,670,139 -$2,172,042 $6.98 86
2022 Q1 26,134,053 $395,189,957 +$20,420,485 $15.12 76
2021 Q4 24,702,968 $541,790,297 +$81,054,878 $21.94 77
2021 Q3 18,711,908 $504,667,012 +$57,523,278 $26.97 61
2021 Q2 16,612,608 $400,026,000 +$731,531 $24.08 54
2021 Q1 15,384,514 $664,816,567 +$34,097,345 $43.38 63
2020 Q4 14,593,004 $602,432,000 +$578,482,000 $41.45 51
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .